RedHill Biopharma Provides 2017 Semi-Annual Business Update

TEL-AVIV, Israel, Jan. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today provided an update on key programs, potential milestones and estimated timelines.

Micha Ben Chorin, RedHill’s CFO, said: “We are heading into 2017 with important potential catalysts in the coming months and with several ongoing Phase III and Phase II programs for gastrointestinal indications. Following the recently announced U.S. co-promotion agreement for Donnatal®1, RedHill is advancing its strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the U.S. This transition is planned to support potential future commercialization of RedHill’s Phase III-stage gastrointestinal drugs, if approved by the FDA. We are backed by strong institutional investors and maintain a debt-free balance sheet with approximately $70 million in cash, allowing us to continue to diligently execute our plans.”


SOURCE : RedHill Biopharma Ltd. 

IKIM'S 25TH ANNIVERSARY CELEBRATIONS

KUALA LUMPUR, Jan 12 (Bernama) -- The Institute of Islamic Understanding Malaysia (IKIM) will celebrate the 25th anniversary of its establishment on the 18 February 2017 or 21 Jamadilawal 1438H. IKIM was established on this date and was registered as a company limited by guarantee under the Companies Act 1965.

IKIM was established with the primary aim of making Islam better understood. Its objectives include: to conduct research and consultancy from the point of view of spirituality, to provide a forum for Muslim and non-Muslim scholars to discuss and analyse various issues, to create awareness and in-depth understanding of current issues as well as to be a source of information to Muslims and non-Muslims at the local and global levels.

http://mrem.bernama.com/viewsm.php?idm=28262

SHOPPERS AT THE OCEANIA MALL TAKE ELEVATOR THROUGH WORLD'S TALLEST CYLINDRICAL AQUARIUM DESIGNED AND BUILT BY INTERNATIONAL CONCEPT MANAGEMENT

MOSCOW, Jan 12 (Bernama-GLOBE NEWSWIRE) -- The world’s tallest cylindrical aquarium housing an elevator ride and walk-through tunnel debuted at the new Oceania Mall in Moscow, Russia. The 24 meter tall acrylic aquarium designed and built by International Concept Management (ICM), is now the focal point for the state-of-the-art shopping center in Russia’s capital city. Photo: http://www.globenewswire.com/NewsRoom/AttachmentNg/82154eae-d021-4cfa-afb6-8ec9942fa03c  ICM designed the aquarium to offer an engaging experience and serve as the centerpiece for shoppers at the mall. To achieve this, ICM designed and built an aquarium that would be architecturally stunning, yet completely immerse guests in an underwater environment.  http://mrem.bernama.com/viewsm.php?idm=28258

SAMMY NETWORKS STARTS DISTRIBUTING "RAMEN SOUL," ENGLISH VERSION OF ITS POPULAR SMARTPHONE RAMEN SHOP MANAGEMENT GAME "RAMEN TAMASHII" WITH OVER 5 MILLION DOWNLOADS

TOKYO, Jan 13 (Bernama-AsiaNet) --

In response to the ramen boom overseas in recent years, Sammy Networks Co., Ltd. started distributing on Jan. 12, 2017, the English version of its popular smartphone ramen shop management game "Ramen Tamashii," which has hit five million downloads in Japan, simultaneously for iPhones (through the App Store) and Android devices (through the Google Play Store) under the title of "Ramen Soul."

http://mrem.bernama.com/viewsm.php?idm=28273

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

TEL-AVIV, Israel, Jan. 12, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) infections. The QIDP designation was granted under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, which is intended to encourage development of new antibiotic drugs for the treatment of serious or life-threatening infections.

The granted QIDP designation allows RedHill to benefit from Fast-Track status, with an expedited development pathway for RHB-104 for the treatment of NTM infections, as well as Priority Review, which provides for a shorter review time by the FDA of a future potential marketing application. If approved for the treatment of NTM infections, RHB-104 would also receive an additional five years of U.S. market exclusivity on top of the standard exclusivity period.     

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. 

COLLIERS INTERNATIONAL EXPANDS IN DENMARK

Acquires market-leading Colliers Denmark affiliate to strengthen global platform

TORONTO, Jan 13 (Bernama-GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) announced today that it has acquired a controlling interest in Colliers International Denmark (“Colliers Denmark”). Senior management of Colliers Denmark will retain the balance of the equity under Colliers International’s unique enterprise partnership model. The acquisition of Colliers Denmark further strengthens Colliers International’s operations in Europe and provides a strong platform for future growth in the important Nordic region. The terms of the transactions were not disclosed.

http://mrem.bernama.com/viewsm.php?idm=28268

RADWARE RESEARCH FINDS DATA LOSS IS TOP CYBER-ATTACK CONCERN

Radware's Global Application and Network Security Report 2016-2017 Finds Ransom Was The #1 Motivation Behind Cyber-Attacks, Malware Was the Most Frequent Type of Attack, and IoT Botnets are a Major Concern

MAHWAH, N.J., Jan 11 (Bernama-GLOBE NEWSWIRE) -- Radware® (NASDAQ:RDWR), a leading provider of cyber security and application delivery solutions ensuring the digital user experience for applications in virtual, cloud, and software-defined data centers, has found that hackers and companies agree on one thing: Data is lucrative. Radware's Global Application and Network Security Report 2016-2017 revealed that 49% of businesses confirmed being the subject of a cyber-ransom campaign in 2016. What's more, 27% of IT professionals surveyed chose data leakage or loss as a key concern when faced with a cyber-attack, while only 19% chose service outage, 16% selected reputation loss, and just 9% cited customer or partner loss.

The full report identifies 2016's major attack trends, outlines industry preparedness, and gives insider views from the front lines to the corner office. Among the biggest trends identified for the current report coverage period:

http://mrem.bernama.com/viewsm.php?idm=28248